Literature DB >> 18318112

[The use of p53 as a tool for human cancer therapy].

V P Almazov, D V Kochetkov, P M Chumakov.   

Abstract

The p53 tumor suppressor is a central component of a system that reinforces genetic stability of somatic cells in animals and humans. Inactivation of this gene occurs virtually in every cancer case, which eliminates results in further rapid accumulation of additional mutations leading to progression of a cancer cell toward more malignant phenotype. The mechanisms of p53 inhibition in cancer include point mutations leading to accumulation of inactive protein, deletion of the whole gene, or its portion, alteration in the genes involved in regulation of activity of p53, and defects in the genes controlled by p53. In addition, oncogenic viruses encode specialized proteins that are entitled to modify p53 functions in order to provide optimal condition for replication of viral genome. These viral proteins play central role in viral carcinogenesis, including 95% of cases of cervical carcinoma in women. The approacheas to restoration of p53 activity depend on particular type of alteration within the p53 pathway. In some cases an effective mean would be introduction of exogenous p53, particularly with the use of adenoviral vectors. There are also approaches in development that target reactivation of mutant proteins, or suppress natural inhibitors of p53. The review summarizes various schemes for therapy and prevention of cancer that are based on our knowledge of the p53 gene functions. Potential usefulness of the approaches for practical applications is discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18318112      PMCID: PMC2634859     

Source DB:  PubMed          Journal:  Mol Biol (Mosk)        ISSN: 0026-8984


  146 in total

Review 1.  Gene therapy strategies to improve the effectiveness of cancer radiotherapy.

Authors:  Svend O Freytag; Jae Ho Kim; Stephen L Brown; Kenneth Barton; Mei Lu; Myung Chung
Journal:  Expert Opin Biol Ther       Date:  2004-11       Impact factor: 4.388

2.  Oncolytic virotherapy as a novel strategy for pancreatic cancer.

Authors:  Makoto Sunamura; Hirofumi Hamada; Fuyuhiko Motoi; Masaru Oonuma; Hisashi Abe; Yukoh Saitoh; Toru Hoshida; Shigeru Ottomo; Noriyuki Omura; Seiki Matsuno
Journal:  Pancreas       Date:  2004-04       Impact factor: 3.327

3.  Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD.

Authors:  Andrei V Budanov; Anna A Sablina; Elena Feinstein; Eugene V Koonin; Peter M Chumakov
Journal:  Science       Date:  2004-04-23       Impact factor: 47.728

4.  Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms.

Authors:  Hui Wang; Patsy Oliver; Zhuo Zhang; Sudhir Agrawal; Ruiwen Zhang
Journal:  Ann N Y Acad Sci       Date:  2003-12       Impact factor: 5.691

Review 5.  Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.

Authors:  Patrick Chène
Journal:  Mol Cancer Res       Date:  2004-01       Impact factor: 5.852

6.  Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis.

Authors:  Jehangir S Wadia; Radu V Stan; Steven F Dowdy
Journal:  Nat Med       Date:  2004-02-08       Impact factor: 53.440

7.  In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Authors:  Lyubomir T Vassilev; Binh T Vu; Bradford Graves; Daisy Carvajal; Frank Podlaski; Zoran Filipovic; Norman Kong; Ursula Kammlott; Christine Lukacs; Christian Klein; Nader Fotouhi; Emily A Liu
Journal:  Science       Date:  2004-01-02       Impact factor: 47.728

8.  Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin.

Authors:  Lance C Pagliaro; Afsaneh Keyhani; Baoshun Liu; Paul Perrotte; Deborah Wilson; Colin P Dinney
Journal:  Urol Oncol       Date:  2003 Nov-Dec       Impact factor: 3.498

9.  Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA.

Authors:  Kyung-Sook Shin; Bruce A Sullenger; Seong-Wook Lee
Journal:  Mol Ther       Date:  2004-08       Impact factor: 11.454

10.  Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy.

Authors:  Gianluca Bossi; Giuseppina Mazzaro; Alessandro Porrello; Marco Crescenzi; Silvia Soddu; Ada Sacchi
Journal:  Oncogene       Date:  2004-01-15       Impact factor: 9.867

View more
  2 in total

Review 1.  Assessing cell and organ senescence biomarkers.

Authors:  Bruno Bernardes de Jesus; Maria A Blasco
Journal:  Circ Res       Date:  2012-06-22       Impact factor: 17.367

2.  Differential miRNA Expression in Human Macrophage-Like Cells Infected with Histoplasma capsulatum Yeasts Cultured in Planktonic and Biofilm Forms.

Authors:  Nayla de Souza Pitangui; Junya de Lacorte Singulani; Janaina de Cássia Orlandi Sardi; Paula Carolina de Souza; Gabriela Rodríguez-Arellanes; Blanca Estela García-Pérez; Francisco Javier Enguita; Fernando R Pavan; Maria Lucia Taylor; Maria José Soares Mendes-Giannini; Ana Marisa Fusco-Almeida
Journal:  J Fungi (Basel)       Date:  2021-01-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.